论文部分内容阅读
目的:探讨艾迪注射液对肺癌放疗患者血清细胞因子的影响。方法:将40例肺癌患者,随机分为治疗组(20例)和对照组(20例),两组均予三维适行放疗(3DCRT),治疗组在此基础上加用艾迪注射液。比较放疗前后两组患者血清中白细胞介素-6(IL-6),肿瘤坏死因子-α(TNF-α)和转化生长因-β(TGF-β)水平的变化及放射性肺炎(RP)发生率的差异。结果:治疗组在放疗结束后细胞因子IL-6,TNF-α和TGF-β的水平明显低于对照组,二者比较差异有显著性(P<0.05);两组RP的发生率相近。结论:艾迪注射液能降低肺癌放疗患者血清细胞因子IL-6,TNF-α和TGF-β的水平,延缓放射性肺炎的进展,有效预防放射性肺炎的发生。
Objective: To investigate the effect of Aidi Injection on serum cytokines in patients with lung cancer undergoing radiotherapy. Methods: Forty patients with lung cancer were randomly divided into treatment group (n = 20) and control group (n = 20). Both groups were treated with 3DCRT. Aidi injection was used in the treatment group. The levels of interleukin-6, tumor necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) and the occurrence of radiation pneumonitis (RP) were compared between the two groups before and after radiotherapy Rate difference. Results: After treatment, the levels of IL-6, TNF-α and TGF-β in the treatment group were significantly lower than those in the control group (P <0.05). The incidence of RP in both groups was similar. Conclusion: Aidi injection can reduce the levels of serum cytokines IL-6, TNF-α and TGF-β in patients with lung cancer and delay the progress of radiation pneumonitis, and effectively prevent the occurrence of radiation pneumonitis.